Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.
about
Modern approaches to HLA-haploidentical blood or marrow transplantationOral complications in hematopoietic stem cell recipients: the role of inflammationHuman mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trialsDepletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients.An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.Current issues in chronic graft-versus-host disease.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Acute graft-versus-host disease of the kidney in allogeneic rat bone marrow transplantation.Circulating Levels of Adipokines Predict the Occurrence of Acute Graft-versus-host DiseaseBlocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis.Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation.Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.Novel role for surfactant protein A in gastrointestinal graft-versus-host disease.PSG9 Stimulates Increase in FoxP3+ Regulatory T-Cells through the TGF-β1 PathwayReduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.Notch simultaneously orchestrates multiple helper T cell programs independently of cytokine signals.Neddylation plays an important role in the regulation of murine and human dendritic cell function.Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host diseaseHIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effectReversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art.Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapyGraft versus host disease: clinical evaluation, diagnosis and management.Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs.Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.Divide and conquer: Blocking graft versus host but not graft versus leukemia T cells with agonist BTLA co-inhibitory signals.Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD.Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease.Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.Role of CD8 Regulatory T Cells versus Tc1 and Tc17 Cells in the Development of Human Graft-versus-Host Disease.
P2860
Q26797506-BB5A153E-1B59-4983-BC0E-F02AF0E1F16EQ27027650-904804ED-762E-4D77-A149-EEDABDFE5CC7Q28071916-D2D6CB6B-BA5F-4DA7-AD07-D7ECC6A54531Q33756801-C114DA53-68DE-4CF3-8421-3DF1A40EBBDBQ33798102-D0F5D952-D433-4D43-BB97-C89450D6051DQ33917187-99C87E8B-2C15-41D8-B872-E063F1FA226CQ35140097-3023F594-39B9-4A4F-A63A-4D298653B079Q35534266-93ABB369-FAC6-4F22-82C4-0005D7050AFCQ35543916-D66B8614-886E-4920-B991-0212B86B16ADQ35669245-8455AD59-88F6-4957-BDC3-F511A9EE58ADQ35813877-98345318-D2C4-4D05-BADA-D1B6DEA54C6EQ35883325-EE0FC5A4-4B91-4AE5-BEB8-38D7576C9DAAQ35954775-4770AFAA-50D3-4309-95FA-4E25A657FD35Q36026057-068DF2DC-BFC7-4CBF-A007-090C97D05575Q36070609-98240F47-FD0A-4C38-979E-EE58C19C1476Q36219724-217ED0AC-3664-4370-90E1-7E18B7EB6D49Q37146430-D411BEAD-10B3-40D7-BF01-74D5A1B14FCFQ37186465-A006EDEF-2A19-40AD-8BDF-DC337227A962Q37215167-62A79CE4-8ACB-4806-A2EF-A38B8786D804Q37383856-CB8C330D-9296-4249-A47E-E4733592CB69Q37635354-262C38BF-B863-4FA6-8F16-9909B1E10049Q37652919-DC67D111-D1F6-455E-B527-6D247E6259B4Q38010239-3675DE52-2EE8-4816-B0F2-C3C634F2C774Q38019320-59406201-76CD-4DAB-88BE-F516AFFBF672Q38090503-6C7BE98A-FF63-4993-9DD4-A4829929FE42Q38197519-CA07179D-28A0-453C-87DE-F9BF29F0FB45Q38202009-2FFF22E0-3116-46AE-ACC0-E19A35B51A89Q38381708-8C90FDB0-4108-4821-AA2C-B053C4A75E81Q38453666-1454D297-642F-4B73-B9C9-556D320A8AEBQ38736579-4987F9C9-05B4-451C-BD85-4D904523398BQ38742867-C20B3615-B6E0-4F38-BBB1-17317E52B9F5Q38753771-3A79D3DF-2586-4C00-A56B-C74FB2A22506Q38816505-57BB92EF-51ED-4702-818B-219624BCB066Q39002164-4C5DAD86-1ABC-4CA3-9A64-3D1015B9A5E1Q39012031-37212A05-65F3-4246-AD49-A1467BD6774BQ39753388-B8DEBC2F-E38A-4505-B57D-534E85683C49Q39982138-36544098-2B4A-4FA8-B54F-7464DCA5F391Q41896478-D8A73D26-2B3B-4F83-88B8-7CF7B52994C6Q42145853-78457BA7-8452-4B38-B839-8401B4DCCDF8Q42155958-50A5A43C-C4E1-4D9C-83A2-2C00310170F3
P2860
Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effector CD4+ T cells, the cyt ...... mething old and something new.
@ast
Effector CD4+ T cells, the cyt ...... mething old and something new.
@en
Effector CD4+ T cells, the cyt ...... mething old and something new.
@nl
type
label
Effector CD4+ T cells, the cyt ...... mething old and something new.
@ast
Effector CD4+ T cells, the cyt ...... mething old and something new.
@en
Effector CD4+ T cells, the cyt ...... mething old and something new.
@nl
prefLabel
Effector CD4+ T cells, the cyt ...... mething old and something new.
@ast
Effector CD4+ T cells, the cyt ...... mething old and something new.
@en
Effector CD4+ T cells, the cyt ...... mething old and something new.
@nl
P2860
P50
P1433
P1476
Effector CD4+ T cells, the cyt ...... mething old and something new.
@en
P2093
William J Murphy
P2860
P304
P356
10.1182/BLOOD-2010-12-290403
P407
P577
2011-01-18T00:00:00Z